Pacific Shuanglin Bio-pharmacy Co., Ltd.
000403.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.47B
Close$
$-0.60
106.3% downside
Current Fair Value
106.3% downsideOvervalued by 106.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.47 Billion |
|---|---|
| Enterprise Value | $9.92 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.44 |
| Beta | 0.48 |
| Outstanding Shares | 939,845,595 |
Return
| Return on Equity | 3.32% |
|---|---|
| Return on Assets | 2.73% |
| Return on Invested Capital | 4.00% |
Valuation & Multiples
| P/E Ratio | 36.3 |
|---|---|
| PEG | -62.37 |
| Price to Sales | 4.75 |
| Price to Book Ratio | 1.19 |
| Enterprise Value to Revenue | 4.01 |
| Enterprise Value to EBIT | 29.17 |
| Enterprise Value to Net Income | 37 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
$0.24
Average shareholder expectationRevenue Estimate
$486.92 M
Average shareholder expectationNext Earnings Call
Expected Date
October 22, 2026
EPS Estimate
$0.28
Average shareholder expectationRevenue Estimate
$486.91 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Pacific Shuanglin Bio-pharmacy Co., Ltd.
2,755 employees
CEO: Xiankui Rong Based in Taiyuan, China, Pacific Shuanglin Bio-pharmacy Co., Ltd. operates extensively within the country, focusing on biochemical engineering, the production of pharmaceutical industry equipment, and medical materials. The company's div...